In a move signaling continued volatility within the privatized Medicare sector, insurance giant Humana has announced plans to shutter a significant portion of its Medicare Advantage (MA) offerings for the upcoming year. This decision marks the second consecutive year of strategic market exits for the company, as it seeks to navigate a complex landscape of rising medical costs, shifting government regulations, and the urgent necessity to restore long-term profitability.
The announcement, which arrived alongside the company’s second-quarter 2026 financial results, underscores a broader industry trend. While insurers like UnitedHealth, Elevance, and Centene have recently reported improved results, the path to sustained, predictable margins remains fraught with challenges. For Humana, the imperative is clear: optimize the portfolio or risk further erosion of investor confidence.
The Strategy: Trimming the Fat to Secure 3% Margins
Humana’s leadership team has articulated a singular, overarching goal: achieving a sustainable operating margin of at least 3% by 2028. CFO Celeste Mellet was unequivocal during the company’s recent earnings call, identifying this target as the organization’s "No. 1 priority."
To reach this benchmark, Humana is systematically divesting from plans that demonstrate lower capital returns. By exiting these underperforming markets, the insurer aims to stabilize its benefit structures and concentrate resources on the most profitable segments of its business.
The scope of this retreat is substantial. Humana anticipates that approximately 600,000 seniors—roughly 8% of its 7.2 million MA members—will be impacted by the plan closures. However, the company is not abandoning these members entirely. Mellet noted that Humana plans to aggressively recapture a significant portion of this volume, targeting a 40% retention rate (approximately 240,000 members) by transitioning them into alternative, more sustainable plan offerings. This "re-capture" strategy mirrors the approach the company successfully employed during the 2025 cycle.
Chronology of the Shift
The current downsizing is not an isolated event but rather the latest chapter in a multi-year effort to recalibrate Humana’s Medicare Advantage footprint:
- Pre-2025: Following the COVID-19 pandemic, the MA industry faced an unprecedented surge in healthcare utilization as seniors sought long-delayed elective procedures and chronic disease management.
- 2025: Humana initiated its first major wave of market exits in response to these rising costs, signaling that the era of aggressive growth at all costs was coming to an end.
- Early 2026: Despite the exits, Humana maintained relatively generous benefits compared to its rivals, leading to an influx of over one million new members.
- Mid-2026 (Q2 Earnings): The insurer announced it would exit MA coverage in three fewer states and 194 fewer counties for 2027, confirming that the "right-sizing" process is far from complete.
- Future Outlook: The company is now focused on the 2027 and 2028 fiscal years, with an emphasis on improving "Star Ratings" to unlock higher quality bonus payments from the Centers for Medicare & Medicaid Services (CMS).
Supporting Data and Financial Performance
Humana’s second-quarter 2026 results paint a picture of a company in transition. Revenue for the quarter reached $40.9 billion, a 26% year-over-year increase driven largely by its recent membership surge and the receipt of higher government rates. Profit also grew by 27% to $694 million.
However, these headline figures masked underlying tensions. While medical cost trends—particularly in inpatient hospital care—were better than anticipated, the company’s forward-looking guidance disappointed Wall Street. Humana reaffirmed its adjusted earnings per share (EPS) guidance, which management views as the truest measure of performance, but significantly slashed its "unadjusted" EPS outlook. The company now expects EPS of at least $6.52 for the year, a steep drop from its previous guidance of $8.36.
This reduction is largely attributed to a decline in the company’s MA Star Ratings. These ratings, which determine the quality bonus payments an insurer receives from CMS, have become a primary source of friction between the industry and federal regulators. Because even a half-star difference can represent hundreds of millions of dollars in revenue, the current instability in ratings has become a major strategic headache for Humana.
Official Responses and Executive Outlook
CEO Jim Rechtin remains publicly optimistic about the company’s trajectory, despite the immediate pressure to cut earnings guidance. Regarding the Star Ratings, Rechtin emphasized that he is proud of the internal progress being made, even as the most recent data showed a slight slip. He reaffirmed the company’s goal of achieving "top quartile" status by the 2028 bonus year.
"We feel good about our substantial progress," Rechtin stated, though he acknowledged the inherent unpredictability of the current regulatory environment. "We don’t know industry thresholds. We cannot guarantee an outcome."
The frustration regarding CMS methodology is shared across the industry. Insurers, including Humana, have been increasingly vocal about what they perceive as an overly complex and opaque scoring system. This dissatisfaction has manifested in a series of lawsuits aimed at forcing CMS to adjust its calculations—legal battles in which Humana has been an active, albeit so far unsuccessful, participant.
The Broader Implications for Seniors and the Industry
The downsizing of Medicare Advantage plans has profound implications for the American healthcare system. For seniors, the most immediate consequence is disruption. As insurers withdraw from specific counties and states, millions of beneficiaries are forced to navigate the administrative burden of selecting new coverage, which can result in changes to their provider networks, pharmacy benefits, and out-of-pocket costs.
For the industry, the current environment is a test of resilience. While the Trump administration provided a boost with a generous rate hike for 2026, the long-term sustainability of the MA model depends on the ability of insurers to manage the high utilization rates of an aging population.
A Diversified Strategy
Humana is not relying solely on MA to drive its future. The company is actively diversifying its revenue streams through its health services division, CenterWell. Recent acquisitions, such as Florida-based providers The Villages Health and MaxHealth, are intended to create a more integrated care model that lowers costs through better management of patient health.
Furthermore, Humana has secured significant wins in the Medicaid space, including a new contract in Illinois and an extension in Florida—its largest Medicaid market. These moves represent a strategic hedge against the volatility inherent in the Medicare Advantage market.
Strengthening Corporate Governance
In a sign of its commitment to navigating this complex future, Humana also announced two strategic additions to its board of directors. The appointment of Paul Smith, an executive at artificial intelligence leader Anthropic, and Frederick Crawford, a veteran of the banking and insurance sectors, suggests that Humana is looking to bolster its capabilities in both technological innovation and financial risk management.
Conclusion
Humana’s latest round of plan exits is a calculated attempt to balance the immediate need for profit stability with the long-term goal of market leadership. By shedding underperforming assets, the company is attempting to insulate itself from the volatility that has plagued the MA sector since the pandemic.
While investors reacted with an 8% dip in share price following the announcement—driven by the lowered unadjusted EPS guidance—the underlying strength of Humana’s growth in Medicaid and health services suggests a company that is repositioning itself for a more stable, albeit more selective, future. For the millions of seniors relying on these programs, however, the message is clear: the landscape of private Medicare remains in a state of flux, necessitating careful planning and vigilance as insurers continue their pursuit of the elusive 3% margin.
